News

Three months of daily treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 safely and effectively reduced blood levels of Huntington’s disease-associated proteins in people with the neurodegenerative condition. That’s according to interim results from a substudy of a Phase 1 clinical trial that specifically showed a greater reduction with…

Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements as a method to track Huntington’s disease activity in clinical trials. The CHDI Foundation is a nonprofit biomedical research organization dedicated to advancing new therapies that can slow the…

Pridopidine may safely and effectively slow Huntington’s disease progression in patients who aren’t taking antidopaminergic medications, which are commonly used for psychiatric symptoms and chorea, or involuntary movements. That’s according to full results from the Phase 3 PROOF-HD clinical trial  (NCT04556656), which tested pridopidine against a…

Swallowing difficulties start in the early stages of Huntington’s disease (HD) and progress over time, affecting both voluntary movements in the mouth and involuntary movements that transport food to the stomach while protecting the airway, a study showed. Researchers used the Swallowing Disturbance Questionnaire (SDQ) to assess swallowing problems,…

An investigational treatment prepared from stem cells found in young teeth appears to be safe and to help adults with Huntington’s disease move better and carry out daily tasks more easily, perhaps by slowing damage to the brain, according to data from a Phase 2 clinical trial. Called…

A postdoctoral researcher at the University of Michigan won a three-year grant to support her work investigating the cellular mechanisms underlying Huntington’s disease. The Huntington’s Disease Society of America (HDSA) awarded its Berman-Topper Family HD Career Development Fellowship to Elizabeth Tidwell, PhD, whose project, “Determining the structure…

Neurodegeneration of the pathways that help relay information from the cerebellum — a brain area involved in motor and cognitive functions — is associated with worsening motor and cognitive symptoms in people with Huntington’s disease, a study reported. Tracking changes in these pathways, or tracts, may help researchers follow…

Both DNA repair and non-repair genes influence how and when Huntington’s disease develops, according to a study based on genetic data from more than 16,000 people with the disorder that also provides new potential targets for treatment. In addition, these findings reveal complex mechanisms behind CAG repeat expansions, the…

A committee of the European Medicines Agency’s (EMA) has recommended that the experimental oral medication pridopidine not be approved for adults with Huntington’s disease. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation will be reviewed by the European Commission, which has final say over therapy…

Early molecular changes in Huntington’s disease appear to be largely due to the loss of normal huntingtin protein function, not just the harmful effects of its mutated form, a new study reports. The scientists found that during nerve cell development, cells without huntingtin showed similar molecular-level disruptions as those…